{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:33:15Z","timestamp":1764646395914,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703014"],"award-info":[{"award-number":["81703014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bcp.2022.115294","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T03:22:57Z","timestamp":1665544977000},"page":"115294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5582-3309","authenticated-orcid":false,"given":"Zhen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuou","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7689","key":"10.1016\/j.bcp.2022.115294_b0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature."},{"issue":"11","key":"10.1016\/j.bcp.2022.115294_b0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2022.115294_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2022.115294_b0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharmthera.2019.06.005","article-title":"Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness","volume":"202","author":"Terlizzi","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"23","key":"10.1016\/j.bcp.2022.115294_b0025","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2022.115294_b0030","doi-asserted-by":"crossref","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","article-title":"Crizotinib resistance: implications for therapeutic strategies","volume":"27","author":"Dagogo-Jack","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2022.115294_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113963","article-title":"Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)","volume":"227","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2022.115294_b0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bcp.2019.05.014","article-title":"Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line","volume":"166","author":"Van Der Steen","year":"2019","journal-title":"Biochem Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115294_b0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1535-7163.MCT-15-0084","article-title":"Activation of EGFR Bypass Signaling by TGFalpha Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells","volume":"15","author":"Tani","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.bcp.2022.115294_b0050","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115294_b0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1541-7786.MCR-16-0211","article-title":"Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer","volume":"15","author":"Miyawaki","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115294_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000011923","article-title":"Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience","volume":"56","author":"Kollmannsberger","year":"1999","journal-title":"Oncology."},{"issue":"5","key":"10.1016\/j.bcp.2022.115294_b0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.14740\/wjon950e","article-title":"Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature","volume":"6","author":"Vennepureddy","year":"2015","journal-title":"World J. Oncol."},{"key":"10.1016\/j.bcp.2022.115294_b0070","article-title":"Topotecan inhibits metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition","volume":"5","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2022.115294_b0075","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/10717544.2020.1772409","article-title":"F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia","volume":"27","author":"Du","year":"2020","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.bcp.2022.115294_b0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115294_b0085","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.cllc.2021.10.009","article-title":"Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations","volume":"23","author":"Hayashi","year":"2022","journal-title":"Clin. Lung Cancer."},{"issue":"24","key":"10.1016\/j.bcp.2022.115294_b0090","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1158\/0008-5472.CAN-17-3370","article-title":"The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer","volume":"78","author":"El Kadi","year":"2018","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2022.115294_b0095","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.bcp.2022.115294_b0100","doi-asserted-by":"crossref","first-page":"111144","DOI":"10.1016\/j.biopha.2020.111144","article-title":"Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways","volume":"134","author":"Liu","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"S1","key":"10.1016\/j.bcp.2022.115294_b0105","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene."},{"issue":"10","key":"10.1016\/j.bcp.2022.115294_b0110","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.7150\/thno.56747","article-title":"The double-edged roles of ROS in cancer prevention and therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics."},{"issue":"4","key":"10.1016\/j.bcp.2022.115294_b0115","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/JCMA.0000000000000703","article-title":"Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers","volume":"85","author":"Liu","year":"2022","journal-title":"J. Chin. Med. Assoc."},{"issue":"1","key":"10.1016\/j.bcp.2022.115294_b0120","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6015-4","article-title":"Reduction of metastatic potential by inhibiting EGFR\/Akt\/p38\/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer","volume":"19","author":"Chowdhury","year":"2019","journal-title":"BMC Cancer."},{"key":"10.1016\/j.bcp.2022.115294_b0125","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejmech.2016.09.066","article-title":"Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways","volume":"125","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2022.115294_b0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-020-0126-x","article-title":"WIP1 promotes cancer stem cell properties by inhibiting p38 MAPK in NSCLC","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2022.115294_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-022-00902-w","article-title":"Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy","author":"Mukherjee","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2022.115294_b0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: Advancements and innovation in the manufacturing process","volume":"154\u2013155","author":"Shah","year":"2020","journal-title":"Adv Drug Deliv Rev."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222003884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222003884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:16:06Z","timestamp":1762096566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222003884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":28,"alternative-id":["S0006295222003884"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115294","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115294"}}